In patients with advanced-stage EGFR variation–positive AD who had received first-line EGFR-TKI, the median OS was 34.3 months (95% CI, 32.2 to 36.8 months) and 43.1 months (95% CI, 39.1 to 49.0 months) for period I (1087 patients) and II (1557 patients), respectively (P < .001). The gene discussed is EGFR; the disease is Alzheimer disease.